Keros Therapeutics (KROS) Change in Accured Expenses (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Change in Accured Expenses data on file, last reported at -$4.4 million in Q4 2025.

• Quarterly Change in Accured Expenses fell 241.03% year-over-year to -$4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.1 million (down 443.19% YoY) and the FY2025 annual result came in at -$10.1 million, down 443.19% from the prior year.
• Change in Accured Expenses climbed to -$4.4 million in Q4 2025, from -$4.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.7 million in Q3 2024 to a low of -$5.4 million in Q1 2024.
• A 5-year average of $302600.0 and a median of $317500.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 4494.85% — and 2023, when it sank 647.65%.
• Tracing KROS's Change in Accured Expenses over 5 years: stood at -$97000.0 in 2021, then soared by 4494.85% to $4.3 million in 2022, then surged by 35.75% to $5.8 million in 2023, then plunged by 122.45% to -$1.3 million in 2024, then slumped by 241.03% to -$4.4 million in 2025.
• The last three Change in Accured Expenses figures came in at -$4.4 million (Q4 2025), -$4.8 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.